Retatrutide Prescribed Online to Washington, D.C. Residents
Medical Weight Loss Treatment in Washington, D.C.
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Washington, D.C.
The nation's capital runs on ambition and tight schedules. OmniRx Health serves DC residents across all eight wards—federal workers on Capitol Hill, policy professionals in Dupont Circle, families in Northeast, and students at Georgetown and Howard. Our telehealth platform is designed for busy Washingtonians who need flexible healthcare that doesn't require taking half a day off to sit in a waiting room. Get expert care during your lunch break or after the Metro stops running.
OmniRx Health providers are licensed by the DC Board of Medicine to deliver telehealth services throughout the District.
DC pharmacies throughout all eight wards provide prescription services with convenient same-day or next-day delivery options.
The District has progressive telehealth laws that support comprehensive virtual care for its residents.
DC requires telehealth coverage parity, and DC Medicaid covers virtual visits for eligible District residents.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Washington, D.C.?
- Yes, the District has progressive telehealth laws supporting virtual healthcare. Licensed providers can offer comprehensive services including consultations and prescriptions.
- Can federal workers in DC use telehealth?
- Telehealth is perfect for DC's federal workforce. Get care during lunch or after work without navigating traffic or taking leave.
- Does DC Medicaid cover telehealth?
- Yes, DC Medicaid covers telehealth services for eligible District residents. Virtual visits are reimbursed at rates comparable to in-person appointments.